Sonoma Pharmaceuticals Inc (SNOA)

Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution

BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

Revenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025United States revenues increased 194% in Q4 2026...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form PRE 14A - Other preliminary proxy statements

Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering

BOULDER, CO / ACCESS Newswire / April 24, 2026 / Sonoma Pharmaceuticals, Inc. (the "Company" or "Sonoma Pharmaceuticals"...

Form EFFECT - Notice of Effectiveness

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

BOULDER, CO / ACCESS Newswire / March 24, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in hypochlorous acid...